ORIC Pharmaceuticals, Inc. (ORIC)

NASDAQ: ORIC · IEX Real-Time Price · USD
5.72
-0.31 (-5.14%)
At close: Feb 3, 2023, 4:00 PM
5.70
-0.02 (-0.35%)
After-hours: Feb 3, 2023, 5:33 PM EST
-5.14%
Market Cap 250.91M
Revenue (ttm) n/a
Net Income (ttm) -91.05M
Shares Out 43.87M
EPS (ttm) -2.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 283,410
Open 5.97
Previous Close 6.03
Day's Range 5.58 - 6.10
52-Week Range 2.36 - 9.61
Beta 0.35
Analysts Buy
Price Target 14.03 (+145.28%)
Earnings Date Mar 20, 2023

About ORIC

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively tar... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 24, 2020
Employees 88
Stock Exchange NASDAQ
Ticker Symbol ORIC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for ORIC stock is "Buy." The 12-month stock price forecast is $14.03, which is an increase of 145.28% from the latest price.

Price Target
$14.03
(145.28% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

2 days ago - GlobeNewsWire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

4 days ago - GlobeNewsWire

7 Top Short-Squeeze Candidates to Watch in February

While everyone knows that in order to have a market, there must be bulls and bears, that's not going to stop people from attempting to garner intense profits from top short-squeeze candidates. To quic...

Other symbols: ELYSGOSSKALAMYOSLNOSTR
4 days ago - InvestorPlace

ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023:  ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer

3 weeks ago - GlobeNewsWire

ORIC Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

1 month ago - GlobeNewsWire

ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study

ORIC inks a collaboration deal with Pfizer for a phase II study evaluating ORIC-533 in combination with the latter's elranatamab in multiple myeloma. Stock up in after-hours trading.

Other symbols: PFE
1 month ago - Zacks Investment Research

Oric's stock rallies on multiple myeloma deal with Pfizer

Shares of Oric Pharmaceuticals Inc. ORIC, +2.04% soared about 56% in premarket trading on Thursday, the day after the company said it will collaborate with Pfizer Inc. PFE, +0.66% to develop a multipl...

Other symbols: PFE
1 month ago - Market Watch

ORIC Pharmaceuticals (ORIC) Stock Rockets 58% on Pfizer Deal

ORIC Pharmaceuticals (NASDAQ: ORIC) stock is rocketing higher after the company revealed a collaboration deal with Pfizer (NYSE: PFE). The big news here is ORIC Pharmaceuticals and Pfizer working to...

Other symbols: PFE
1 month ago - InvestorPlace

ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer

ORIC and Pfizer have entered into a clinical development collaboration for a Phase 2 study of ORIC-533 in combination with elranatamab in multiple myeloma

1 month ago - GlobeNewsWire

ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

1 month ago - GlobeNewsWire

ORIC Pharmaceuticals to Present at the Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

3 months ago - GlobeNewsWire

ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update

Initial Phase 1b data for three ongoing clinical studies expected to be reported in 1H 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer

3 months ago - GlobeNewsWire

ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

3 months ago - GlobeNewsWire

ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update

Three ongoing single agent Phase 1 programs, ORIC-533 in multiple myeloma,  ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, all expected to report initial data in 1H 2023

6 months ago - GlobeNewsWire

ORIC Pharmaceuticals to Present at the Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

8 months ago - GlobeNewsWire

ORIC Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

SOUTH SAN FRANCISCO and SAN DIEGO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address m...

9 months ago - GlobeNewsWire

ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update

Three ongoing single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, all expected to report initial data in 1H2023

9 months ago - GlobeNewsWire

ORIC Pharmaceuticals Presents Promising Preclinical Data on Three Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

10 months ago - GlobeNewsWire

7 Stocks That Insiders Are Buying Now. Should You?

Here are seven stocks that have recently seen large amounts of insider purchases: Asana (NYSE:ASAN) Ford (NYSE:F) GameStop (NYSE:GME) Eastman Kodak (NYSE:KODK) Oric Pharmaceuticals (NASDAQ:ORIC) Revol...

Other symbols: ASANFGMEKODKRVMDSOFI
11 months ago - InvestorPlace

ORIC Stock Plunges on Discontinuation of Oncology Candidate

ORIC declines on discontinuation of pipeline candidate ORIC-101 following planned interim analyses of two phase Ib studies.

11 months ago - Zacks Investment Research

Why ORIC Pharmaceuticals Shares Are Plunging Today

ORIC Pharmaceuticals Inc (NASDAQ: ORIC) has decided to discontinue the further development of ORIC-101 after interim analyses from the two Phase 1b studies, wherein ORIC-101 did not demonstrate suffic...

11 months ago - Benzinga

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

Announces decision to discontinue development of ORIC-101

11 months ago - GlobeNewsWire

ORIC Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Update Conference Call

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

11 months ago - GlobeNewsWire

ORIC Pharmaceuticals Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

ORIC-533 oral presentation and poster presentation to highlight potential of small molecule inhibitor of CD73 as a treatment for multiple myeloma

11 months ago - GlobeNewsWire

ORIC Pharmaceuticals to Participate in the Guggenheim 2022 Oncology Conference

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

1 year ago - GlobeNewsWire